双極性障害(躁うつ病):治療薬開発パイプライン動向(2016年下半期版)

◆英語タイトル:Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016
◆商品コード:DATA70209298
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2016年11月16日
◆ページ数:122
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site LicenseUSD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprisewide (Global Site License)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における双極性障害(躁うつ病)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・双極性障害(躁うつ病)の概要
・双極性障害(躁うつ病)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・双極性障害(躁うつ病)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・双極性障害(躁うつ病)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・双極性障害(躁うつ病)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides an overview of the Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline landscape.

Bipolar disorder was formerly called manic depression. It is a form of major affective disorder, or mood disorder, defined by manic or hypomanic episodes. Symptoms include decreased appetite and/or weight loss, or overeating and weight gain, fatigue, decreased energy, being slowed down, insomnia, early-morning awakening, or oversleeping, restlessness and irritability. The predisposing factors include age, stress and family history. Treatment includes anticonvulsants, antipsychotics and antidepressants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Bipolar Disorder (Manic Depression) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Bipolar Disorder (Manic Depression) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 3, 10, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.Bipolar Disorder (Manic Depression).

Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bipolar Disorder (Manic Depression) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bipolar Disorder (Manic Depression) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bipolar Disorder (Manic Depression) (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bipolar Disorder (Manic Depression) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bipolar Disorder (Manic Depression) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Bipolar Disorder (Manic Depression) Overview 10
Therapeutics Development 11
Pipeline Products for Bipolar Disorder (Manic Depression) – Overview 11
Pipeline Products for Bipolar Disorder (Manic Depression) – Comparative Analysis 12
Bipolar Disorder (Manic Depression) – Therapeutics under Development by Companies 13
Bipolar Disorder (Manic Depression) – Therapeutics under Investigation by Universities/Institutes 15
Bipolar Disorder (Manic Depression) – Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Bipolar Disorder (Manic Depression) – Products under Development by Companies 19
Bipolar Disorder (Manic Depression) – Products under Investigation by Universities/Institutes 21
Bipolar Disorder (Manic Depression) – Companies Involved in Therapeutics Development 22
Aequus Pharmaceuticals Inc. 22
Amorsa Therapeutics Inc. 23
AstraZeneca Plc 24
Biogen Inc 25
Delpor, Inc. 26
Intas Pharmaceuticals Ltd. 27
Intra-Cellular Therapies, Inc. 28
Johnson & Johnson 29
KemPharm, Inc. 30
Mapi Pharma Ltd. 31
Navya Biologicals Pvt Ltd 32
Neurocrine Biosciences Inc 33
Omeros Corporation 34
Otsuka Holdings Co., Ltd. 35
Pfizer Inc. 36
Reviva Pharmaceuticals Inc. 37
SK Biopharmaceuticals Co., Ltd. 38
Sumitomo Dainippon Pharma Co Ltd 39
Zogenix, Inc. 40
Zysis Limited 41
Bipolar Disorder (Manic Depression) – Therapeutics Assessment 42
Assessment by Monotherapy Products 42
Assessment by Combination Products 43
Assessment by Target 44
Assessment by Mechanism of Action 46
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
(cycloserine + lurasidone hydrochloride) – Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
aripiprazole – Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
aripiprazole CR – Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
aripiprazole ER – Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
CB-1407 – Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
CB-2803 – Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Cenobamate – Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
CNV-1061436 – Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ebselen – Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
Endoxifen – Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
ITI-007 – Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
JNJ-18038683 – Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
KP-303 – Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
lurasidone hydrochloride – Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
NAV-003 – Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
paliperidone palmitate – Drug Profile 85
Product Description 85
Mechanism Of Action 85
R&D Progress 85
PGW-5 – Drug Profile 86
Product Description 86
Mechanism Of Action 86
R&D Progress 86
quetiapine fumarate ER – Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
risperidone – Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
risperidone – Drug Profile 90
Product Description 90
Mechanism Of Action 90
R&D Progress 90
risperidone – Drug Profile 91
Product Description 91
Mechanism Of Action 91
R&D Progress 91
RP-5063 – Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
SKL-PSY – Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
Small Molecule for Bipolar Disorder – Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
Small Molecule for Cancer and Neurodegenerative Disease – Drug Profile 96
Product Description 96
Mechanism Of Action 96
R&D Progress 96
Small Molecule to Antagonize GPR78 for Bipolar Disorder and Schizophrenia – Drug Profile 97
Product Description 97
Mechanism Of Action 97
R&D Progress 97
Small Molecule to Inhibit VMAT-2 for Bipolar Disorder, Movement Disorders and Schizophrenia – Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Small Molecule to Target GPR50 for Bipolar Disorder and Metabolic Disorders – Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
Small Molecules to Antagonize NMDA Receptor and CHRNA7 for Central Nervous System – Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Small Molecules to Target NMDA Receptor for Bipolar Depression – Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
Synthetic Peptides to Inhibit IMPase for Bipolar Disorder – Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
ziprasidone mesylate – Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
Bipolar Disorder (Manic Depression) – Dormant Projects 104
Bipolar Disorder (Manic Depression) – Discontinued Products 107
Bipolar Disorder (Manic Depression) – Product Development Milestones 108
Featured News & Press Releases 108
Oct 27, 2016: Sunovion Announces Positive Clinical Study Results for Latuda (lurasidone HCl) in Adolescents with Schizophrenia 108
Oct 18, 2016: NeuroRx Solidifies Intellectual Property Position Receives Notice of Allowance by US Patent Office 109
Sep 16, 2016: Sunovion to Present Data on Latuda (lurasidone) at the 29th European College of Neuropsychopharmacology (ECNP) Congress 110
Aug 09, 2016: Astellas Submits New Drug Application for Extended-Release Tablets of Quetiapine Fumarate in Japan 111
Jun 01, 2016: NeuroRx Awarded First Prize in Annual Israel BIOMED Startup Competition 111
May 23, 2016: Sunovion Announces Publication of Data Evaluating the Long-Term Safety and Tolerability of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression 112
May 12, 2016: Sunovion to Present Data on Latuda (lurasidone HCl) at the 169th Annual Meeting of the American Psychiatric Association 113
Feb 25, 2016: Intra-Cellular Therapies Provides Product Update 114
Feb 04, 2016: Aequus Announces Positive Results from Single-Dose Bioavailability Study of Aripiprazole Transdermal Patch 116
Dec 23, 2015: Intra-Cellular Therapies Reports Initiation of Patient Enrollment for ITI-007 Phase 3 Clinical Trials in Bipolar Depression 116
Dec 16, 2015: NeuroRx Provides Clinical Development Update for Cyclurad, a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder 117
Nov 16, 2015: Aequus Receives Approval from Health Canada to Initiate Phase 1 Clinical Trial of Aripiprazole Transdermal Patch 118
Jul 23, 2015: Positive Preclinical Results and Patent Allowed for Aequus’ Once-Weekly Transdermal Aripiprazole 119
Jul 22, 2015: Intra-Cellular Therapies Announces Phase 3 Clinical Development Program for the Treatment of Depressive Episodes Associated With Bipolar Disorder 120
May 28, 2015: Aequus Announces Positive Skin Irritation Results for Once-Weekly Transdermal Aripiprazole 120
Appendix 121
Methodology 121
Coverage 121
Secondary Research 121
Primary Research 121
Expert Panel Validation 121
Contact Us 121
Disclaimer 122

List of Tables
Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016 11
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Development, H2 2016 18
Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2016 21
Bipolar Disorder (Manic Depression) - Pipeline by Aequus Pharmaceuticals Inc., H2 2016 22
Bipolar Disorder (Manic Depression) - Pipeline by Amorsa Therapeutics Inc., H2 2016 23
Bipolar Disorder (Manic Depression) - Pipeline by AstraZeneca Plc, H2 2016 24
Bipolar Disorder (Manic Depression) - Pipeline by Biogen Inc, H2 2016 25
Bipolar Disorder (Manic Depression) - Pipeline by Delpor, Inc., H2 2016 26
Bipolar Disorder (Manic Depression) - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 27
Bipolar Disorder (Manic Depression) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016 28
Bipolar Disorder (Manic Depression) - Pipeline by Johnson & Johnson, H2 2016 29
Bipolar Disorder (Manic Depression) - Pipeline by KemPharm, Inc., H2 2016 30
Bipolar Disorder (Manic Depression) - Pipeline by Mapi Pharma Ltd., H2 2016 31
Bipolar Disorder (Manic Depression) - Pipeline by Navya Biologicals Pvt Ltd, H2 2016 32
Bipolar Disorder (Manic Depression) - Pipeline by Neurocrine Biosciences Inc, H2 2016 33
Bipolar Disorder (Manic Depression) - Pipeline by Omeros Corporation, H2 2016 34
Bipolar Disorder (Manic Depression) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 35
Bipolar Disorder (Manic Depression) - Pipeline by Pfizer Inc., H2 2016 36
Bipolar Disorder (Manic Depression) - Pipeline by Reviva Pharmaceuticals Inc., H2 2016 37
Bipolar Disorder (Manic Depression) - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 38
Bipolar Disorder (Manic Depression) - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 39
Bipolar Disorder (Manic Depression) - Pipeline by Zogenix, Inc., H2 2016 40
Bipolar Disorder (Manic Depression) - Pipeline by Zysis Limited, H2 2016 41
Assessment by Monotherapy Products, H2 2016 42
Assessment by Combination Products, H2 2016 43
Number of Products by Stage and Target, H2 2016 45
Number of Products by Stage and Mechanism of Action, H2 2016 47
Number of Products by Stage and Route of Administration, H2 2016 49
Number of Products by Stage and Molecule Type, H2 2016 51
Bipolar Disorder (Manic Depression) - Dormant Projects, H2 2016 104
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..1), H2 2016 105
Bipolar Disorder (Manic Depression) - Dormant Projects (Contd..2), H2 2016 106
Bipolar Disorder (Manic Depression) - Discontinued Products, H2 2016 107

List of Figures
Number of Products under Development for Bipolar Disorder (Manic Depression), H2 2016 11
Number of Products under Development for Bipolar Disorder (Manic Depression) - Comparative Analysis, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Clinical Stage Development, H2 2016 17
Comparative Analysis by Early Stage Products, H2 2016 18
Assessment by Monotherapy Products, H2 2016 42
Number of Products by Top 10 Targets, H2 2016 44
Number of Products by Stage and Top 10 Targets, H2 2016 44
Number of Products by Top 10 Mechanism of Actions, H2 2016 46
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 46
Number of Products by Routes of Administration, H2 2016 48
Number of Products by Stage and Routes of Administration, H2 2016 48
Number of Products by Molecule Types, H2 2016 50
Number of Products by Stage and Molecule Types, H2 2016 50

【レポートのキーワード】

双極性障害(躁うつ病)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 双極性障害(躁うつ病):治療薬開発パイプライン動向(2016年下半期版)(Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2016)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆